Onset of multiple myeloma with rheumatic polymyalgia
https://doi.org/10.21886/2219-8075-2019-10-4-98-104
Abstract
A clinical observation of a patient presented with a typical clinic of rheumatic polymyalgia (RPM), which was a manifestation of myeloma. The relationship between rheumatic polymyalgia and giant cell arteritis (GCA) is well known, but association of RPM with lymphoproliferative diseases is rarely reported. In this case there was a clinical improvement in the patient’s condition aft er chemotherapy treatment.
About the Authors
E. R. Israelyan
Rostov State Medical University
Russian Federation
Russian Federation
6 year student of the medical and preventive faculty,
Rostov-on-Don
C. S. Golovataya
Rostov State Medical University
Russian Federation
Russian Federation
6 year student of the medical and preventive faculty,
Rostov-on-Don
O. K. Bondarenko
Rostov State Medical University
Russian Federation
Russian Federation
6 year student of the medical and preventive faculty,
Rostov-on-Don
A. V. Nayda
Rostov State Medical University
Russian Federation
Russian Federation
6 year student of the medical and preventive faculty,
Rostov-on-Don
A. K. Pudeeva
Rostov State Medical University
Russian Federation
Russian Federation
5 year student of the medical and preventive faculty,
Rostov-on-Don
References
1. Volkova MA. Clinical Oncohematology: Guide for Physicians. Moscow: Medicine; 2001. (In Russian).
2. Vasilyev VI, Gorodetsky VR , Logvinenko OA, Sedyshev SK, Aleksandrova EN, et al. Rheumatic masks of plasma cell dyscrasias. Rheumatology Science and Practice.. 2012;51(2):35- 43. (In Russ.) doi: 10.14412/1995-4484-2012-1271
3. Rukavitsyn OA. Hematology: national guidelines. Moscow: GEOTAR-Media; 2017. (In Russ.).
4. Talamo G, Farooq U, Zangari M, Liao J, Dolloff NG, et al. Beyond the CRAB Symptoms: A Study of Presenting Clinical Manifestations of Multiple Myeloma. Clinical Lymphoma Myeloma and Leukemia. Elsevier BV; 2010;10(6):464—8. doi: 10.3816/clml.2010.n.080
5. Sterling G. Rheumatology secret. 3rd ed. GEOTAR-Media; 2018. (In Russ.).
6. Naschitz JE, Rosner I, Rozenbaum M, Elias N, Yeshurun D. Cancer-associated rheumatic disordersclues to occult neoplasia. Seminars in Arthritis and Rheumatism. 1995;24(4):231—41. doi: 10.1016/s0049-0172(95)80033-6
7. Keung YK, Yung C, Wong JW, Shah F, Cobos E. Association of temporal arteritis, retinal vasculitis, and xanthomatosis with multiple myeloma: case report and literature review. Mayo Clinic Proceedings. 1998 Jul 1;73(7):657—60. doi: 10.4065/73.7.657
8. Gelber M. Polymyalgia rheumatica as the presenting symptom of multiple myeloma. Harefuah. 1995;128(9):544-549.
9. Speed CA, Haslock I. Polymyalgia rheumatica, temporal arteritis and malignancy. Postgraduate Medical Journal. BMJ. 1995;71(838):500—2. doi: 10.1136/pgmj.71.838.500
10. Ilfeld D, Barzilay J, Vana D, Ben-Bassat M, Joshua H, Pick I. IgG monoclonal gammopathy in four patients with polymyalgia rheumatica. Annals of the Rheumatic Diseases. BMJ. 1985;44(7):501—501. doi: 10.1136/ard.44.7.501
11. Kalra L, delamere JP. Lymphoreticular malignancy and monoclonal gammopathy presenting as polymyalgia rheumatica. Rheumatology. 1987;26(6):458—9. doi: 10.1093/rheumatology/26.6.458
12. Zykova AS, Novikov PI, Moiseev SV. Adult dermatomyositis: new classifi cation criteria and modern treatment. Klinicheskaya pharmakologia i terapia. 2017; 26(2):83-92. (In Russ.).
13. Karateev D.E., Olyunin Y.A., Luchikhina E.L., Karateyev D.E., Olyunin Y.A., Luchikhina E.L. New ACR/EULAR 2010 classifi cation criteria for rheumatoid arthritis: a step forward in its early diagnosis. Rheumatology Science and Practice. 2011;49(1):10-15. doi: 10.14412/1995-4484-2011-861 (In Russ.).
14. Bashkova IB, Busalaeva EI. Rheumatic polymyalgy: frequent disease, which is rarely diagnosed. RMJ. Medical review. 2017; 1:48—52. (In Russ.).
15. Nasonov EL. Rheumatology: Russian clinical guidelines. Moscow: GEOTAR-Media; 2019. (In Russ.). 16. Bessmeltsev MM, Abdulkadyrov KM. Multiple myeloma: Guide for Physicians. Moscow: SIMK; 2016. (In Russ.).
16. Islam A, Myers K, Cassidy DM, Ho SF, De Silva M. Muscle Involvement in Multiple Myeloma: Report of a Patient Presenting Clinically as Polymyositis. Hematology. 1999;4(2):123—5. doi: 10.1080/10245332.1999.11746437
17. Vallabhajosyula S, Bekur R, Bhat R, Gnanadev N, Belurkar S. Polymyositis associated with non-secretory myeloma — a case report. Australasian Medical Journal. 2011;4(4):205—9. doi: 10.4066/amj.2011.661
18. Md Serajul I, Pavel K. Multiple Myeloma Associated with Dermatomyositis: A Short Report and Mini-Review. International Journal of Blood Research and Disorders. 2018;5(1). doi: 10.23937/2469-5696/1410029
19. Santos-Faria D, Leite Silva J, Sousa-Neves J, Ramos Rodrigues J, Afonso C, Peixoto D. Systemic sclerosis and myositis as a paraneoplastic syndrome secondary to multiple myeloma. Acta Reumatologica Portuguesa. 2018; 4:316-317.
20. Gertz MA, Kyle RA. Myopathy in primary systemic amyloidosis. Journal of Neurology, Neurosurgery, and Psychiatry. 1996; 60:655-660.
21. Guglielmi V, Nowis D, Tinelli M, Malatesta M, Paoli L, Marini M, et al. Bortezomib-Induced Muscle Toxicity in Multiple Myeloma. Journal of Neuropathology & Experimental Neurology. 2017;76(7):620—30. doi: 10.1093/jnen/nlx043
22. Kikuchi M, Inagaki T, Ueda R. Multiple myeloma with infi ltration into skeletal muscle aft er injections of granulocytecolony stimulating factors. Geriatrics and Gerontology International. 2004;4(4):250—4. doi: 10.1111/j.1447-0594.2004.00256.x
23. Stephenson AL. Myositis associated graft -versus-hostdisease presenting as respiratory muscle weakness. BMJ; 2001;56(1):82—4. doi: 10.1136/thorax.56.1.82
24. Colombo I, Fruguglietti ME, Napoli L, Sciacco M, Tagliaferri E, Della Volpe A, et al. IgD Multiple Myeloma Paraproteinemia as a Cause of Myositis. Neurology Research International. 2010;2010:1—3. doi: 10.1155/2010/808474
25. Manzo C, Natale M. Polymyalgia rheumatica and cancer risk: the importance of the diagnostic set. Open Access Rheumatology: Research and Reviews. 2016;8:93-95. doi: 10.2147/OARRR.S116036
26. Satybaldaev AM, Demidova NV, Savushkina NM, Gordeev AV. Polymyalgia rheumatica. Rheumatology Science and Practice. 2018;56(2):215-227. (In Russ).
27. Braga WMT, Atanackovic D, Colleoni GWB. The Role of Regulatory T Cells and TH17 Cells in Multiple Myeloma. Clinical and Developmental Immunology. 2012;2012:1—4. doi: 10.1155/2012/293479
28. Jung MK, Kwak J-E, Shin E-C. IL-17A-Producing Foxp3+ Regulatory T Cells and Human Diseases. Immune Network . 2017;17(5):276. doi: 10.4110/in.2017.17.5.276
29. Mazerolles F, Stolzenberg M-C, Pelle O, Picard C, Neven B, Fischer A, et al. Autoimmune Lymphoproliferative Syndrome-FAS Patients Have an Abnormal Regulatory T Cell (Treg) Phenotype but Display Normal Natural TregSuppressive Function on T Cell Proliferation. Frontiers in Immunology. 2018; 9. doi: 10.3389/fimmu.2018.00718
30. Ji J, Liu X, Sundquist K, Sundquist J, Hemminki K. Cancer risk in patients hospitalized with polymyalgia rheumatica and giant cell arteritis: a follow-up study in Sweden. Rheumatology. 2010;49(6):1158—63. doi: 10.1093/rheumatology/keq040
31. Muller S, Hider SL, Belcher J, Helliwell T, Mallen CD. Is cancer associated with polymyalgia rheumatica? A cohort study in the General Practice Research Database. Annals of the Rheumatic Diseases BMJ. 2013;73(10):1769—73. doi: 10.1136/annrheumdis-2013-203465
Review
For citations:
Israelyan E.R., Golovataya C.S., Bondarenko O.K., Nayda A.V., Pudeeva A.K. Onset of multiple myeloma with rheumatic polymyalgia. Medical Herald of the South of Russia. 2019;10(4):98-104. (In Russ.) https://doi.org/10.21886/2219-8075-2019-10-4-98-104
Views:
4125
Email this article 